EndoPredict vs Oncotype DX for Predicting Breast Cancer Recurrence

Article

In this Medical News Minute, developed exclusively for Cancer Network, Dr. Bobby Lazzara discusses a recent study that compared EndoPredict and Oncotype DX, which both predict the likelihood of a breast cancer recurrence.

In this Medical News Minute, developed exclusively for Cancer Network, Dr. Bobby Lazzara discusses a recent study that compared EndoPredict and Oncotype DX, which both predict the likelihood of a breast cancer recurrence.

Recent Videos
Conducting trials safely within a community setting lies at the heart of a successful collaboration between Northwell Health and START.
We are seeing that, in those patients who have relapsed/refractory melanoma with survival measured as a few weeks and no effective treatments, about a third of these patients will have a response.
We have the current CAR [T-cell therapies], which target CD19; however, we need others.
The expertise of START's network may streamline the availability of clinical trial enrollment and novel treatment options among patients with cancer.
“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.
A new START center in New York may give patients with advanced malignancies an opportunity to access novel therapies in the community setting.
Barry Paul, MD, listed cilta-cel, anito-cel, and arlo-cel as 3 of the CAR T-cell therapies with the most promising efficacy in patients with multiple myeloma.
START is the largest early phase oncology network in the community-based setting, according to Geraldine O’Sullivan Coyne, MD, MRCPI, PhD.
Jose Sandoval Sus, MD, discussed standard CAR T-cell therapies in patients across multiple high-risk lymphoma indications.
Related Content
The drug that the companion diagnostic identifies patients for, zongertinib, received FDA approval for HER2-mutant NSCLC on August 8, 2025.

FDA Approves NGS-Based Companion Diagnostic for Zongertinib in NSCLC

Roman Fabbricatore
August 12th 2025
Article

The drug that the companion diagnostic identifies patients for, zongertinib, received FDA approval for HER2-mutant NSCLC on August 8, 2025.

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Obesity and weight gain are associated with adverse outcomes following breast cancer diagnosis.

GLP-1 Receptor Agonist Use and Weight Change in Patients With Breast Cancer

Sherry Shen, MD;Bethina Liu, MD;Chad Fanti, MD;Maria Bromberg, MPH;Yuan Chen, PhD;Cassandra Chang;Neil M. Iyengar, MD
August 12th 2025
Article

Patients with breast cancer experience significant weight loss after using GLP-1 receptor agonists, highlighting potential benefits for obesity management in this population.

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

Jacob Sands, MD
August 4th 2025
Podcast

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Findings demonstrate a need to move beyond disease-related factors to address disparities in HMA treatment patterns among those with MDS.

Data Show Disparities in HMA Use Among Myelodysplastic Syndrome Populations

Russ Conroy
August 11th 2025
Article

Findings demonstrate a need to move beyond disease-related factors to address disparities in HMA treatment patterns among those with MDS.

The decision is based on phase 3 VERITAC-2 trial data showing a significant PFS improvement vs fulvestrant in ESR1-mutant ER+/HER2– breast cancer.

FDA Accepts NDA for Vepdegestrant in ESR1-Mutant ER+/HER2– Breast Cancer

Roman Fabbricatore
August 11th 2025
Article

The decision is based on phase 3 VERITAC-2 trial data showing a significant PFS improvement vs fulvestrant in ESR1-mutant ER+/HER2– breast cancer.